In previous decades, traditional R&D methods have yielded blockbuster drugs, allowing companies to recoup the costs of development. Nowadays, with patent expiries, more complex disease targets, pricing pressures and increased regulatory requirements, the industry must find a different model to adaptto these changes.
As we are experiencing a lag between R&D spending and the extraction of value from that investment, open innovation presents an opportunity to break the mould of current drug research, innovate exponentially without expanding R&D investment and speed the development of tomorrow’s lifesaving medicines for diseases.
VENUE: Crowne Plaza Amsterdam-South
WHO SHOULD ATTEND
- CXOs, SVPs, VPs, Heads, Directors of major Pharmaceutical/Biotech companies responsible for: Biomedical Research, Drug Discovery, External R&D, Medicinal Chemistry, Alliance Management, Intellectual Property, Non-Clinical Safety, External Networks and Partnerships, Strategic Alliances, Collaborative Research, etc.
- Professors, scientists and researchers from Universities and Research Centres with an expertise in: Biomedical Research, Biology, Medicinal Chemistry, Drug Discovery, Intellectual Property, etc.
- Representatives from Governmental bodies and Non-profit drug R&D organizations
KEY TOPICS
The challenges of sustained productivity:
Are we on the “patent cliff“ as the patents for blockbuster drugs expire?
Could Open Innovation provide answers to these challenges?
Is sharing of intellectual property a barrier to Open Innovation?
Engaging in Public-Private Partnerships to enhance drug development
Successful examples of sharing patents, compounds, data and expertise:
Collaboration between Academia and the corporate sector, Crowd sourcing initiatives, Neglected diseases drug discovery, etc.
Are we on the “patent cliff“ as the patents for blockbuster drugs expire?
Could Open Innovation provide answers to these challenges?
Is sharing of intellectual property a barrier to Open Innovation?
Engaging in Public-Private Partnerships to enhance drug development
Successful examples of sharing patents, compounds, data and expertise:
Collaboration between Academia and the corporate sector, Crowd sourcing initiatives, Neglected diseases drug discovery, etc.





























